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Abstract
Background: Atherosclerosis is a major cause of death in developed world. Atherosclerosis is characterized by low-
density lipoprotein deposition in the arterial wall which ultimately begets the formation of lesions. Rupture of
lesions finally leads to clinical events such as heart attack and stroke. Atherosclerosis is a complication associated
with diabetes. In patients with diabetes, the risk of atherosclerosis is three to five folds greater than in non-
diabetics. Our previous study showed that a herbal extract of Radix Astragali, Radix Codonopsis and Cortex Lycii,
namely SR10, could improve glucose homeostasis both in vitro and in vivo. In this study, we want to further
investigate the efficacy of SR10 in treating atherosclerosis.
Method: The inhibitory effect of SR10 on low-density lipoprotein oxidation was investigated using free radical-
induced erythrocyte hemolysis model and copper ion-induced low-density lipoprotein oxidation model. Since
vascular smooth muscle cell proliferation and migration are important processes in atherogenesis, we also
examined the effect of SR10 in inhibiting these events.
Results: Our results showed that SR10 inhibited erythrocyte hemolysis with IC50 value at 0.25 mg/ml and
significantly prolonged low-density lipoprotein oxidation in vitro. SR10 attenuated platelet derived growth factor-
BB-induced vascular smooth muscle cell proliferation by promoting cell cycle arrest at G0/G1 phase as well as
inhibiting vascular smooth muscle cell migration.
Conclusion: The potential application of SR10 in treating atherosclerosis has been implied in this study. Animal
model will be needed to further verify the efficacy of SR10 in future.
Keywords: Atherosclerosis vascular smooth muscle cell, proliferation, migration
Background
Diabetes mellitus (DM) affects more than 170 million
people in the world. Due to associated complications,
the mortality rate in DM patients is much higher than
that in non-DM patients. Of various diabetic complica-
tions, atherosclerosis represents the major mortal threat
to DM patients [1,2]. Many studies have been carried
out to find the association between diabetes and
atherosclerosis.
It was found that glucose-enhanced low density lipo-
protein (LDL) oxidation and glucose-mediated enhance-
ment of LDL oxidation was partially blocked by
superoxide dismutase [3,4].
Oxidized LDL is involved in atherogenesis by affecting
cytokine production, endothelium-derived relaxing fac-
tor-mediated vascular reactivity and foam cell formation
[5,6].
These findings explain how chronic hyperglycemia of
diabetes accelerates lipoprotein oxidation, thereby pro-
moting diabetic vascular disease.
It was found that free radicals are one of the major
causes of atherogenesis. Oxygen derived free radicals are
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any medium, provided the original work is properly cited.very important mediators of cell injury. These free radi-
cals include superoxide, hydrogen peroxide and nitric
oxide. Collectively, the high activity of reactive oxygen
species (ROS) determines chemical changes in virtually
all cellular components, leading to DNA and protein
modification and lipid peroxidation [7]. In addition,
excessive ROS in diabetes is thought to promote athero-
genesis by affecting several steps. Firstly, it facilitates
monocyte and macrophage recruitment. Secondly, it
increases lipid deposition in the intimal layer. Thirdly, it
promotes the proliferation and migration of smooth
muscle cells [8]. One of the principal regulators of mito-
genesis in vascular smooth muscle cells is platelet-
derived growth factor-BB (PDGF-BB). The signaling
pathway of PDGF-BB-induced mitogenesis involves the
activation of extracellular regulated kinases 1 and 2
(ERK1/2) [9]. ERK1/2-mediated pathway was also shown
to be important for PDGF-BB-induced cell cycle pro-
gression in vascular smooth muscle cells. Within the
a r t e r i a lm e d i a ,s m o o t hm u s c l ec e l l sa r em o s t l yi nt h e
quiescent stage (i.e. G0/G1 phase of the cell cycle). Upon
vessel injury, smooth muscle cells migrate into the
intima, where they transit through G1 phase and enter
the S phase.
In our previous study, a herbal mixture, namely SR10,
comprising the aqueous extracts of Radix Astragali,
Radix Codonopsis and Cortex Lycii was examined for its
anti-diabetic and anti-oxidative effects both in vitro and
in vivo [10,11]. In the diabetic mouse model, the activ-
ities and expression of the anti-oxidant enzymes, cata-
lase and superoxide dismutase, were up-regulated when
treated with SR10. This anti-oxidative property implied
the therapeutic potential of SR10 in treating athero-
sclerosis. Therefore, in this study, we investigated the
effect on oxidative resistance of LDL which is an impor-
tant step in initiating atherosclerosis. Furthermore, the
effect of SR10 on PDGF-BB-induced vascular smooth
muscle cell proliferation and migration was examined.
Methods
Sources and authentication of herbal materials
Radix Astragali, dried root of Astragalus membranaceus
(Fisch.) Bge., Radix Codonopsis, dried root of Codonopsis
pilosula (Franch.) Nannf. and Cortex Lycii, dried root bark
of Lycium chinense Mill., were purchased from a herbal
pharmaceutical company in Hong Kong. All herbs were
authenticated by morphological observation and thin layer
chromatography (TLC) according to the method described
in Pharmacopoeia of the People’s Republic of China 2000
[12]. The reference compounds and reference herbs used
in authentication were purchased from National Institute
for the Control of Pharmaceutical and Biological Products
in China. The authenticated voucher specimen were
deposited in the Institute of Chinese Medicine, The
Chinese University of Hong Kong with voucher numbers
(Radix Astragali, 2005-2580; Radix Codonopsis, 2005-
2597; Cortex Lycii, 2005-2601).
Preparation of herbal extracts
SR10 was prepared as described previously by boiling
214.3 g of Radix Astragali,2 1 4 . 3go fRadix Codonopsis
and 71.4 g of Cortex Lycii in 5 L of distilled water for 2
hours under reflux [10] and collecting the extract.
Another 5 L of distilled water was added and the boiling
process was repeated. Two batches of water extract were
mixed together and centrifuged to remove the herbal
debris. The extract was vacuum dried and the resulting
herbal powder was stored at -20°C until use. The pow-
der contained 25.5 g/100 g of the starting raw material.
Cell Culture
A7r5, a rat aorta smooth muscle cell line, was purchased
from American Type Culture Collection (ATCC number
CRL-1444) and maintained in RPMI-1640 medium sup-
plemented with 10% fetal bovine serum and 1% penicil-
lin-streptomycin in a humidified atmosphere of 5% CO2
at 37°C.
Measurement of free radical-induced erythrocyte
hemolysis
Blood was collected from adult Sprague-Dawley (SD) rat
from thoracic aorta by heparinised tube. Red blood cells
were obtained by centrifugation at 1500 × g for 10 min-
utes and washed twice with 0.15 M NaCl solution. After
centrifugation, 20% RBC suspension was obtained by
r e s u s p e n d i n gR B Ci nf o u rt i m e st h ev o l u m eo f0 . 1 5M
NaCl solution. RBC lysis reaction was set up in micro-
centrifuge tubes, each containing 10% RBC suspension,
100 mM of 2,2’-azo-bis-(2-amidinopropane) dihy-
drochloride (AAPH) and ascorbic acid (positive control)
or various concentrations of SR10 in a total volume of 1
ml. Control was set up using PBS instead of SR10. RBC
with ascorbic acid or SR10 was added first, and the reac-
tion initiated by adding 100 mM of AAPH. The mixtures
were then incubated in an oscillator at 37°C for 200 min-
utes. After incubation, the mixtures were diluted with
PBS or distilled water by 20-fold respectively. The diluted
mixtures were centrifuged at 1500 × g for 10 minutes.
The supernatant (200 μl) of each mixture was transferred
to a 96-well microtiter plate for measurement at 540 nm
by microplate reader. Percentage inhibition of RBC
hemolysis was calculated by the equation: Inhibition % =
(A - B) × 100%, whereas A = (DWsample -P B S sample)/
DWsample; B = (DWcontrol - PBScontrol)/DWcontrol
Measurement of LDL peroxidation
The reaction was set up in a quartz cuvette, each con-
taining 75 μgo fL D L ,5μM of copper (II) chloride and
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ml. LDL and the testing drug were added to the cuvette
before adding copper (II) chloride to initiate the reac-
tion. Conjugated dienes formation was continually mon-
itored at 37°C by measuring UV absorption at 234 nm
in 5-minute intervals for a total of 24 hours. The lag
time (L.T.) for the formation of conjugated dienes was
determined to be the intercept of the slopes for the lag
and propagation phases, and was compared to the con-
trol (using PBS instead of SR10).
Cell proliferation assay
A7r5 cells (0.5 × 10
4/well) were seeded in each well of
96-well culture plate. After overnight incubation, PDGF-
BB (25 ng/ml) was added to the cells in the presence or
absence of various concentrations of SR10. Cells without
the addition of PDGF-BB and SR10 was used as negative
control. After further incubation for 24 hours, 3-(4,5-
dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium (MTT)
assay was performed to measure cell viability [11].
Briefly, medium was removed and 40 μlo fM T Ts o l u -
tion (5 mg/ml in PBS) was added to each well. After
incubation for 4 hours at 37°C, MTT solution was
removed and 100 μl of dimethyl sulfoxide was added to
dissolve the crystals formed. Then, absorbance at 540
nm was read using a microplate reader. The percentage
cell viability was calculated as [Absorbance(treatment)/
Absorbance(negative control)] × 100%.
Determination of DNA synthesis
DNA synthesis in A7r5 cells was determined by
3H-thy-
midine uptake assay. Cells (2 × 10
3/well) were seeded in
a 96-well plate and incubated overnight. The cells were
synchronized by starving in 1% fetal bovine serum for
another 24 hours. PDGF-BB was added in the presence
or absence of various concentrations of SR10 and
further incubated at 37°C with 5% CO2 for 24 hours.
Subsequently, tritiated thymidine (0.5 μCi per well) was
added into each well and incubated for 6 hours. After
that, the cells were harvested on glass fiber filters by a
cell harvester. Radioactivity in the filters was measured
by Microplate Scintillation and Luminescence Counter
(Topcount NXT™).
Cell cycle analysis by PI staining using flow cytometer
Cells (2 × 10
5/well) were seeded in a 6-well plate and
incubated overnight. The cells were synchronized by
starving in 1% fetal bovine serum for another 24 hours.
PDGF-BB was then added in the presence or absence of
various concentrations of SR10 and further incubated at
37°C with 5% CO2 for 24 hours. Cell cycle analysis was
performed by PI staining using flow cytometry as
described previously [13]. In brief, the cells were har-
vested, washed twice with PBS and fixed overnight with
70% ethanol. After fixation, the cells were washed with
PBS and resuspended in 400 μlo fP B S ,5 0μlo fR N a s e
A (10 mg/ml) and 10 μl of propidium iodide (PI, 2 mg/
ml). The cells were further incubated at 37°C for 30
minutes before analysis by FACSort flow cytometry
(Becton Dickinson) using ‘Cell Quest’ software. The cell
population was chosen by forward scatter (FSC) light
and side scatter (SSC) light. The signal was detected by
FL3 channel for PI with log scale.
Cell migration assay
Cell migration assay was performed in modified Boyden
chambers using Transwell (Costar) culture chambers
with membrane pore size of 8 μm. A7r5 cells (1.5 ×
10
4/well) in serum-free DMEM were loaded in the
upper compartment (100 μl). PDGF-BB dissolved in
plain DMEM was placed in the lower compartment (600
μl) in the presence or absence of various concentrations
of SR10. The chamber was incubated for 3 hours at 37°
C in a humidified atmosphere containing 5% CO2/95%
air. Cells on the membrane were fixed in 1% parafor-
maldehyde and stained in hematoxylin. Non-migrated
cells on the upper surface were scraped away gently.
The number of migrated cells at the lower surface was
determined under microscope. Five regions were
counted per filter. Three chambers were used for each
treatment and control group. The experiment was per-
formed in triplicate.
Western blot analysis of extracellular regulated kinases 1
and 2 (ERK1/2) and cyclin D1
Western blot was performed as described previously
[14]. After appropriate treatment, the cells were lysed in
buffer containing 0.02% Aprotinin, 2% SDS, 10% gly-
cerol, 62.5 mM Tris-HCl, pH 6.8 and the protein con-
centration was determined using the bicinchonic acid
protein assay. Samples with equal amount of protein (25
μg) were analysed by polyacrylamide gel electrophoresis.
The proteins were then transferred to a polyvinylidene
fluoride (PVDF) membrane. After blocking with 10%
non-fat milk in PBS-T (PBS with 0.1% Tween-20), the
membranes were incubated overnight with antibodies
against ERK1/2 or cyclin D1 or b-actin at 4°C. The
membranes were further incubated with horseradish
peroxidase-conjugated secondary antibodies for 1 hour
and the signal detected by enhanced chemiluminescence
(ECL) detection reagents (GE Healthcare).
Data analysis
All experimental results were presented as mean ± stan-
dard deviation (S.D.). The Mann-Whitney test was used
for comparison between PDGF-BB-treated group and
each SR10 treatment group. The test was two-sided
with a significance level of 0.05.
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Inhibition of AAPH-induced RBC hemolysis
2,2’-azo-bis-(2-amidinopropane) dihydrochloride
(AAPH) is a well-known free radical generator. In the
absence of AAPH, hemolysis of RBC was negligible.
When RBCs were incubated with 100 mM AAPH for
200 minutes, about 93% of hemolysis was detected (data
not shown). However, percentage inhibition of hemoly-
sis was increased when RBCs were incubated with
increasing concentrations of SR10. In Figure 1, SR10
was shown to inhibit up to 70% hemolysis at concentra-
tion 1 mg/ml, with IC50 value at 0.25 mg/ml. Ascorbic
acid (vitamin C) was used as a positive control with
IC50 value at 0.1 mg/ml.
Prolongation of LDL oxidation
Lag phase prolongation, as calculated by lag time(sample)
- lag time(control), was used to measure the antioxidant
property of the sample to protect from LDL oxidation.
The lag time was determined graphically as the x-inter-
cept of the tangent to the propagation curve. Figure 2A
showed the result of one of the representative trial. Data
shown in Figure 2B was the average of three trials. SR10
increased the lag time from 85 minutes (PBS control) to
480 minutes and 1000 minutes at concentrations of 10
μg/ml and 20 μg/ml, respectively. Ascorbic acid, as a
positive control, increased the lag time to 370 minutes
and 525 minutes at concentrations 1 μg/ml and 2 μg/
ml, respectively.
Inhibition of vascular smooth muscle cell proliferation
The effect of SR10 on vascular smooth muscle cell pro-
liferation was evaluated. A7r5 cells were incubated with
PDGF-BB in the presence or absence of SR10 for 24
hours. Cell viability was examined by MTT assay. When
A7r5 cells were stimulated with PDGF-BB for 24 hours
in the absence of SR10, cell growth (which is directly
proportional to absorbance measured in MTT assay)
was significantly increased. However, the addition of
SR10 suppressed this PDGF-BB-stimulated proliferation
in a concentration-dependent manner with significant
effect at concentrations of 2.5 mg/ml and 5 mg/ml. This
inhibition of cell proliferation was not due to toxicity of
SR10 as SR10 alone did not induce any significant
change (Figure 3).
The effect of SR10 on cell growth was also detemined
by measuring DNA synthesis. PDGF-BB highly increased
-40
-20
0
20
40
60
80
100
0 0.1 0.2 0.3 0.4 0.5 0.6
Concentration (mg/ml)
%
 
i
n
h
i
b
i
t
i
o
n
 
o
f
 
R
B
C
 
h
e
m
o
l
y
s
i
s
SR10
Ascorbic acid
Figure 1 Effect of SR10 on AAPH-induced hemolysis in
erythrocytes. Erythrocyte suspension was incubated with PBS (set
as 0% inhibition), various concentrations of ascorbic acid (positive
control) or SR10 in the presence of 100 mM AAPH for 200 minutes
at 37°C. Values are expressed as mean ± S.D. of three independent
experiments.
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Figure 2 Effect of SR10 on prolongation of copper ion-induced
LDL oxidation. LDL in PBS was incubated with 5 μM CuCl2 at 37°C
in the presence or absence of SR10, and ascorbic acid (positive
control). Conjugated diene formation was measured by determining
the absorbance at 234 nm at every 5 minutes for totally 24 hours. A
figure showing one representative experiment of three trials was
shown in panel A. Lag time was determined as the intercept of the
slopes for the lag phase and propagation phase. Difference of lag
time between treatment and control (PBS only) was defined as lag
phase prolongation. Results of lag phase prolongation time from
three independent trials was shown in panel B. Values are expressed
as mean ± S.D. for three independent experiments. By Mann-
Whitney test, significant difference when compared to PBS control
was indicated by # p < 0.01.
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Page 4 of 93H-thymidine incorporation into DNA but the increase
was inhibited by co-treatment of SR10 in a concentra-
tion-dependent manner (Figure 4).
Cell cycle arrest at G0/G1 and inhibition of expression of
cyclin D1 and ERK1/2
The effect of SR10 on cell cycle progression was evalu-
ated by PI staining. In quiescent A7r5 cells, the
populations in G0/G1,Sa n dG 2/M phase were 69.52%,
10.56% and 19.93%, respectively. When the cells were
stimulated by PDGF-BB for 24 hours, cell cycle progres-
sion from G0/G1 to S and G2/M phase was observed.
However, treatment with various concentrations of SR10
blocked G0/G1-S phase transition. The population of
G0/G1 phase was increased from 48.18% to 57.29%,
59.22% and 66.02% when PDGF-BB-stimulated cells
were treated with SR10 at concentrations of 1.25 mg/ml,
2.5 mg/ml and 5 mg/ml, respectively. Populations in S
phase were decreased from 25.13% to 21.22%, 19.19%
and 13.03%, respectively, while in G2/M phase, the
populations were decreased from 26.69% to 21.48%,
21.59% and 20.95%, respectively (Figure 5A).
Since SR10 arrested cell cycle progression at G0/G1
phase, G1 phase-regulated protein cyclin D1 expression
was examined by Western blot. The results showed that
SR10 mildly suppressed expression of cyclin D1 which
was up-regulated by PDGF-BB (Figure 5B).
ERK1/2-mediated pathway is important for PDGF-BB-
induced cell cycle progression in vascular smooth mus-
cle cells. Western blot analysis showed that SR10 sup-
pressed the proliferation of VSMC via the ERK pathway
and phosphorylated ERK1/2 is one of the regulators
affected (Figure 5C).
Suppression of vascular smooth muscle cell migration
Figure 6A shows the view of the lower membrane after
cell migration through it. PDGF-BB greatly induced vas-
cular smooth muscle cell migration. However, when
SR10 was placed at the lower chamber with PDGF-BB,
cell migration was inhibited significantly at all concen-
trations tested (Figure 6B).
Discussion
Proliferation and migration of VSMCs are the basic
pathological changes in atherosclerosis that lead ulti-
mately to the formation of atherosclerotic plaque. Oxi-
dized LDL (ox-LDL) has been shown to be participated
in the initiation and development of atherosclerotic pla-
que by initiating foam cell formation, promoting the
recruitment of circulating monocytes into the intima as
well as activating the proliferation of vascular smooth
muscle cells [15]. Oxidants for LDL oxidation include
reactive oxygen species such as superoxide anion and
peroxynitrite, as well as peroxidase and metal ions [16].
Since ox-LDL was formed by oxidation of LDL, anti-oxi-
dant that can prevent this process may decrease the
development of atherosclerosis. Thus, in this study, we
measured the anti-oxidative activity of SR10 using
AAPH-induced RBC hemolysis model and then assess
the delay of LDL oxidation.
AAPH is a well-known free radical generator which
induce lipid peroxidation on the RBC membrane. Our
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Figure 3 Effect of SR10 on PDGF-BB-stimulated proliferation of
A7r5 cells. Cells were incubated with PDGF-BB (25 ng/ml) for 24
hours in the absence or presence of various concentrations of SR10.
Cells incubated with various concentrations of SR10 without PDGF-
BB were used to indicate the cytotoxicity of SR10. After 24 hours,
MTT assay was performed to measure the cell viability in different
treatments. Percentage of cell viability without treatment of PDGF-
BB or SR10 was set as 100% (negative control). Percentage of cell
viability of other treatment groups was calculated against negative
control. Data are expressed as mean ± S.D. with eight replicates for
each of three independent experiments. By Mann-Whitney test,
significant difference when compared to PDGF-BB alone was
indicated by *p < 0.05 or # p < 0.01.
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Figure 4 Effect of SR10 on PDGF-BB-induced
3H-thymidine
incorporation in A7r5 cells. Cells were treated with PDGF-BB (25 ng/
ml) for 24 hours in the absence or presence of SR10 and incorporation
of
3H-thymidine was measured. Data was expressed as mean ± S.D.
with six replicates for each of three independent experiments. By
Mann-Whitney test, significant difference when compared to PDGF-BB
alone was indicated by *p < 0.05 or # p < 0.01.
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Figure 5 Effect of SR10 on cell cycle distribution of PDGF-BB-treated A7r5 cells. After starving with 1% fetal bovine serum for 24 hours,
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result of one representative experiment (A). The expression level of cyclin D1 was detected by Western blot. The figure is a representative of
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ANOVA. Treatment of 1.25, 2.5 or 5 mg/ml of SR10 all suppressed the expression of cyclin D1 which was induced by PDGF. Statistical
significance was indicated by ** p < 0.01 or *** p < 0.001 (B). The expression level of ERK1/2 was detected by Western blot. The figure is a
representative of three independent experiments with similar results. The quantitation of ERK1/2 was performed by analyzing three sets of data
by One-way ANOVA. Treatment of 1.25, 2.5 or 5 mg/ml of SR10 all suppressed the expression of cyclin D1 which was induced by PDGF (data
shown in red boxes). Statistical significance was indicated by *** p < 0.001 (C).
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Figure 6 Effect of SR10 on PDGF-BB-induced migration of A7r5 cells in a transwell migration assay. A7r5 cells were loaded in the upper
chamber while PDGF-BB (25 ng/ml) was loaded in the lower chamber in the absence or presence of various concentrations of SR10. After 3-
hour incubation, migrated cells were observed in the lower surface of the membrane (A). Number of migrated cells was counted for five regions
per filter. Data were expressed as mean ± S.D. with three replicates in each of three independent trials. By Mann-Whitney test, significant
difference when compared to PDGF-BB alone was indicated by *p < 0.05 or # p < 0.01 (B).
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RBC hemolysis in a dose-dependent manner with IC50
found at 0.25 mg/ml. This showed that SR10 had an
anti-oxidative property. We next examined the effect of
SR10 on the oxidative resistance of LDL. Conjugated
diene formation in LDL by copper ion-mediated oxida-
tion was measured. In Figure 2, lag time is obtained
from the graph to measure the ability to inhibit LDL
oxidation. A longer lag time represents a stronger anti-
oxidative activity to prolong LDL oxidation. Our results
demonstrated that SR10 could inhibit LDL from being
oxidized by copper ion. The results of both AAPH-
induced and copper ion-induced lipid peroxidation indi-
cated that SR10 is an anti-oxidant which could inhibit
LDL oxidation.
Since LDL oxidation induces the initiation and devel-
opment of atherosclerotic plaque, we next examined the
effect of SR10 in proliferation and migration of VSMC
which are important stages strongly suggested in athero-
sclerotic plaque formation. Vascular proliferation
reduces intimal thickening in arteries where the devel-
opment of atherosclerosis occurs. Controlling vascular
proliferation by regulating cell cycle progression is a
new therapeutic strategy for atherosclerosis [17]. Many
growth factors have been shown to function as mitogens
for VSMC. One of them is PDGF-BB. PDGF-BB is
important in vascular repair after cellular injury. It has
been implicated in neointima formation and inhibitors
of PDGF-BB signal transduction have been shown to
decrease the formation [18]. PDGF binds to its receptor
PDGFR which subsequently activate signal transduction,
for example, through the PI3K pathway, and lead to
downstream regulation of gene expression and the cell
cycle. PDGF-BB is also found to trigger the production
of extracellular matrix (ECM) and secretion of cytokines
which lead to structural changes of the media and allow
the VSMC to migrate from media to the inflammatory
site [19]. Our study involved the use of PDGF-BB to
induce VSMC proliferation and migration, and the sub-
sequent inhibition of these processes by SR10 was inves-
tigated. PDGF-BB induced VSMC proliferation which
was suppressed by the addition of SR10 (Figure 3). The
suppression was not due to cytotoxicity of SR10 because
SR10 alone did not decrease cell viability when com-
pared with negative control. Result of
3H-thymidine
uptake assay also suggested that SR10 decreased DNA
synthesis which is an indication of cell proliferation (Fig-
ure 4).
The anti-proliferation of VSMC by SR10 was further
confirmed by cell cycle analysis. Cells are activated by
entering from the quiescent (G0)s t a g et oG 1 phase. To
begin the DNA replication, the cell enters S phase for
synthesis and then G2/M phase for mitosis. Our results
indicated that PDGF-BB arrested the cells at S phase
and G2/M phase. This means that PDGF-BB activated
cell proliferation (Figure 5A). The results demonstrated
that SR10 suppressed PDGF-BB-induced VSMC prolif-
eration by decreasing cell cycle arrest at S and G2/M
phase. Besides cell populations in different phases, regu-
lation on different cyclin-CDK complexes was also stu-
died. Cyclin D-CDK4 and cyclin E-CDK2 complexes
regulate G1 and S phases transition while cyclin A-
CDK2 and cyclin B-CDK1 regulate G2/M phase transi-
tion [20]. The results of Western blot showed that
PDGF-BB-induced expression of cyclin D1 was sup-
pressed by co-treatment of SR10 in a dose-dependent
manner (Figure 5B). The decrease in G1 and S phases
transition consolidated the result that SR10 inhibited
PDGF-BB-induced S and G2/M phase cell cycle arrest,
and hence inhibited VSMC proliferation. The signaling
pathway of PDGF-BB-induced mitogenesis involved the
activation of ERK1/2 which was shown in Figure 5C. In
fact, it has been previously reported that baicalin (an
active component from Scutelleria baicalensis) and cory-
noxeine (isolated from Uncaria rhynchophylla) also sig-
nificantly inhibited PDGF-induced ERK1/2 activation
[21,22].
Besides cell proliferation, VSMC migration from
media to intimal space is also important in the develop-
ment of atheroma. In our study, a transwell migration
assay was applied to investigate the inhibitory effect of
SR10 on VSMC migration. SR10 was shown to be inhi-
bitory for VSMC migration in a dose-dependent manner
(Figure 6).
Actually, VSMC proliferation and migration are two
independent processes. SR10 was found to be effective
in inhibiting both processes, implying that it is a poten-
tial inhibitor of atherosclerosis. This is a preliminary
study using in vitro models. Different concentrations of
SR10 were used in different experiments because differ-
ent cellular models and modes of action are involved.
For example, red blood cells were used to measure the
inhibitory effects of SR10 on free radical-induced hemo-
lysis while A7r5 is the smooth muscle cell line used for
the measurement of proliferation and migration. In
future, in vivo model should be applied to consolidate
the observations. A concentration range of 1.25 - 5 mg/
ml of SR10 was used to treat vascular smooth muscle
cell in vitro. In vivo experiment will be required to test
if same concentration range in mg/ml of SR10 can be
reached in the host’s body.
SR10 is a novel formulation and no previous study has
been done for the effects of SR10 on anti-atherosclero-
sis. In addition, as SR10 is comprised of three herbs, the
components in these herbs may have their own interac-
tions. Therefore, it is not easy to predict the physiologi-
cal effects and the bioavailable concentration of SR10 in
human or animals. Future in vivo experiments must be
Chan et al. BMC Complementary and Alternative Medicine 2011, 11:32
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sclerotic treatment.
Conclusions
T h i ss t u d yd e m o n s t r a t e dt h a tS R 1 0 ,ah e r b a lm i x t u r eo f
Radix Astragali, Radix Codonopsis and Cortex Lycii,
exhibited antioxidant activities which was effective in
inhibiting red blood cell hemolysis and prolonging LDL
oxidation. The anti-atherogenic effects of SR10 was also
indicated by the attenuation of PDGF-induced VSMC
proliferation and migration. The results of this study
implied the potential application of SR10 in treating
atherosclerosis.
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